{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:03:03Z","timestamp":1787896983878,"version":"build-2784847793"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27219","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T22:24:01Z","timestamp":1710195841000},"page":"e27219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A case of multiple ART intolerance responds to Albuvirtide and Dolutegravir: Case report and literature review"],"prefix":"10.1016","volume":"10","author":[{"given":"Zhong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cao","family":"Guiying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi\u00e8 Ji\u00e0n","family":"P\u00edng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e27219_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064702","article-title":"Accelerated aging in HIV\/AIDS: novel biomarkers of senescent human CD8+ T cells","volume":"8","author":"Chou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e27219_bib2","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/09540121.2012.663882","article-title":"HealthCall: technology-based extension of motivational interviewing to reduce non-injection drug use in HIV primary care patients \u2013 a pilot study","volume":"24","author":"Aharonovich","year":"2012","journal-title":"AIDS Care"},{"key":"10.1016\/j.heliyon.2024.e27219_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10461-016-1545-0","article-title":"The role of ARV associated adverse drug reactions in influencing adherence among HIV-infected individuals: a systematic review and qualitative meta-synthesis","volume":"21","author":"Li","year":"2017","journal-title":"AIDS Behav."},{"key":"10.1016\/j.heliyon.2024.e27219_bib4","first-page":"893","article-title":"Clinical efficacy of Albuvirtide regimen in patients with severe AIDS","volume":"41","author":"He","year":"2020","journal-title":"Sichuan Medical Journal"},{"key":"10.1016\/j.heliyon.2024.e27219_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40265-020-01284-1","article-title":"Advances in long-acting agents for the treatment of HIV infection","volume":"80","author":"Rana","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e27219_bib6","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","article-title":"Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study","volume":"133","author":"Su","year":"2020","journal-title":"Chinese Med J"},{"key":"10.1016\/j.heliyon.2024.e27219_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12981-016-0091-1","article-title":"Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r showed potent efficacy in HIV-1 patients","volume":"13","author":"Zhang","year":"2016","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.heliyon.2024.e27219_bib8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.heliyon.2024.e27219_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkv425","article-title":"Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake","volume":"71","author":"Elliot","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.heliyon.2024.e27219_bib10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","article-title":"Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: a systematic review and network meta-analysis","volume":"19","author":"Snedecor","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e27219_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032599","article-title":"Biophysical property and broad anti-HIV activity of albuvirtide, a 3-Maleimimidopropionic acid-modified peptide fusion inhibitor","volume":"7","author":"Chong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e27219_bib12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e27219_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomised clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402403250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402403250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:44:23Z","timestamp":1782247463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402403250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S240584402403250X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27219","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of multiple ART intolerance responds to Albuvirtide and Dolutegravir: Case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27219"}}